Valuation: TTY Biopharm Company Limited

Market Cap 19.22B 596M 516M 484M 441M 830M 56.85B 842M 5.69B 2.22B 28.46B 2.24B 2.19B 94.91B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 19.22B 596M 516M 484M 441M 830M 56.85B 842M 5.69B 2.22B 28.46B 2.24B 2.19B 94.91B EV / Sales 2026 *
2.73x
EV / Sales 2027 * -
Free-Float
76.9%
Yield 2026 *
-
Yield 2027 * -
1 day-0.39%
1 week+0.91%
Current month+3.90%
3 months+2.66%
6 months-7.65%
Current year-5.15%
1 week 76.1
Extreme 76.1
78.2
1 month 73.9
Extreme 73.9
79.5
Current year 71.6
Extreme 71.6
87
1 year 71.6
Extreme 71.6
87
3 years 66.2
Extreme 66.2
87
5 years 66.2
Extreme 66.2
88.5
10 years 54.2
Extreme 54.2
137
Manager TitleAgeSince
Chief Executive Officer - 2022-04-17
Director of Finance/CFO - 2015-12-30
Compliance Officer - 2022-04-17
Director TitleAgeSince
Director/Board Member - 1995-07-23
Director/Board Member - 2016-06-23
Director/Board Member 70 2016-06-23
Change 5-day change 1-year change 3-year change Capi.($)
-0.39%+0.91%+2.38%+2.25% 598M
+0.43%+4.31%+90.84%+130.99% 1,083B
+0.41%+1.27%+50.98%+50.05% 626B
-0.53%+1.04%+25.23%+63.46% 442B
-0.92%+0.22%+48.34%+37.85% 363B
-1.32%-0.21%+29.07%+36.81% 295B
-1.20%-2.78%+5.56%+6.09% 248B
+0.45%+2.05%+46.04%+58.54% 224B
-2.51%+1.77%-6.55%-51.74% 210B
+0.07%+3.12%+13.21%+69.84% 168B
Average -0.55%+1.52%+30.51%+40.41% 365.97B
Weighted average by Cap. -0.26%+2.19%+49.21%+65.95%

Financials

2026 *2027 *
Net sales 7.05B 218M 189M 177M 162M 304M 20.84B 309M 2.09B 815M 10.43B 820M 803M 34.79B -
Net income - -
Net Debt - -
Logo TTY Biopharm Company Limited
TTY Biopharm Co Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of pharmaceutical preparations. The Company mainly operates through six business segments including Cancer Drug segment, Healthcare segment, Anti-Infective Drug segment, Domestic Cardiovascular and Gastrointestinal Drug segment, Mainland Medical Drug segment and the Other segment. The main products include oncology medicines, anti-infective medicines and health care medicines. Oncology medicines are mainly anti-cancer and auxiliary drugs. Anti-infective medicines are mainly back-line antimicrobial agents and influenza vaccines. Medical and health care medicines are mainly gastrointestinal health care, bone health care, metabolic health care, infection treatment drugs. The Company distributes its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
26-08-12 NT$77.30 -0.39% 601,746
26-08-11 NT$77.60 +0.52% 501,306
26-08-10 NT$77.20 +0.92% 497,365
26-08-07 NT$76.50 +0.53% 540,556
26-08-06 NT$76.10 -0.65% 292,929
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
77.30TWD
Average target price
92.00TWD
Spread / Average Target
+19.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4105 Stock